Back to Search
Start Over
Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
- Source :
-
Journal of Neuroimmunology . Aug2015, Vol. 285, p4-12. 9p. - Publication Year :
- 2015
-
Abstract
- Alemtuzumab, a monoclonal antibody directed against human CD52, is used in the treatment of MS. To characterize the impact of anti-CD52 administration, a monoclonal antibody to mouse CD52 (anti-muCD52) was generated and evaluated in EAE mouse models of MS. A single course of anti-muCD52 provided a therapeutic benefit accompanied by a reduction in the frequency of autoreactive T lymphocytes and production of pro-inflammatory cytokines. Examination of the CNS revealed a decrease in infiltrating lymphocytes, demyelination and axonal loss. Electrophysiological assessment showed preservation of axonal conductance in the spinal cord. These findings suggest that anti-CD52 therapy may help preserve CNS integrity. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01655728
- Volume :
- 285
- Database :
- Academic Search Index
- Journal :
- Journal of Neuroimmunology
- Publication Type :
- Academic Journal
- Accession number :
- 108453750
- Full Text :
- https://doi.org/10.1016/j.jneuroim.2015.05.018